Clinical Trials

55 enrolled

Phase 1/2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

357 enrolled

Ovarian Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03085147 2026-02-12

A Dye for the Detection of Cancer of the Tongue and Mouth

23 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT02734004 2026-01-29

MEDIOLA

BreastGastrointestinalGynecologicThoracic

264 enrolled 32 charts

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04086485 2025-12-17

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

56 enrolled

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT03212742 2025-12-04

OLA-TMZ-RTE-01

91 enrolled

CNS

Glioma

NCT02484404 2025-11-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06785636 2025-11-14

P300

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT04972110 2025-10-30

ATTACC

156 enrolled 19 charts

Other solid neoplasm

Advanced Solid Tumor, Adult

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

220 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02755844 2025-10-02

ENDOLA

35 enrolled

Endometrial Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05405309 2025-06-03

CORONADO CLL

LymphoidOther hematologic neoplasm

5 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

54 enrolled

Breast

Breast Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

19 enrolled 11 charts

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT05933265 2025-03-06

Study of LP-184 in Patients With Advanced Solid Tumors

175 enrolled

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT04826198 2024-12-05

REVOCAN

13 enrolled

Ovarian Neoplasms

NCT05700669 2024-09-19

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

3 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT06525298 2024-09-19

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

144 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

7 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01513174 2024-06-28

GOAL

186 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

45 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06298084 2024-03-29

ICARUSBREAST02

152 enrolled

Breast

Breast Cancer Metastatic

NCT02446704 2022-02-07

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Phase 1/2 Unknown

66 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01650376 2018-03-23

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Phase 1/2 Unknown

52 enrolled